COLEC12 Promotes Tumor Progression and Is Correlated With Poor Prognosis in Gastric Cancer

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2023 Dec 19

PMID 38112409

Authors

Xiangfei Sun

Qiang Zhang

Ping Shu

Xiaohan Lin

Xiaodong Gao

Kuntang Shen

Affiliations

Soon will be listed here.

Abstract

Purpose: Collectin subfamily member 12, a transmembrane scavenger receptor C-type lectin, is aberrantly expressed in various cancers. However, its physiological role in gastric cancer remains somewhat unclear. This study aimed to investigate the Collectin subfamily member 12 expression pattern in human gastric cancer and its role in gastric cancer progression.

Methods: The Kaplan-Meier method was used for survival analysis. The univariate and multivariate Cox proportional hazards regression models were used to identify independent predictors for progression-free survival and overall survival. The effects of Collectin subfamily member 12 on gastric cancer cell proliferation, migration, invasion, and apoptosis were detected through the cell counting kit-8 assay, colony formation assay, wound healing assay, transwell assay, and flow cytometry analysis, respectively. Additionally, the correlation between Collectin subfamily member 12 expression and immune cell infiltration was analyzed through bioinformatics.

Results: Collectin subfamily member 12 was highly expressed in advanced gastric cancer (T3-T4, pathologic stage III-IV). High Collectin subfamily member 12 expression was correlated with a worse progression-free survival and overall survival in the gastric cancer patients. , cell line studies revealed that Collectin subfamily member 12 promoted gastric cancer cell proliferation, migration, and invasion and inhibited gastric cancer cell apoptosis. The bioinformatics analysis further demonstrated that the Collectin subfamily member 12 expression level positively correlated with infiltration of several immune cells, such as M2 macrophages, dendritic cells, neutrophils, and regulatory T cells, suggesting that Collectin subfamily member 12 may also play a role in suppressing tumor immune response in gastric cancer.

Conclusions: Collectin subfamily member 12 was identified as a novel predictive marker and target for the clinical treatment of gastric cancer.

Citing Articles

Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses.

Lu C, Huang X, Huang M, Liu C, Xu J BMC Neurol. 2025; 25(1):82.

PMID: 40033250 PMC: 11874834. DOI: 10.1186/s12883-025-04091-x.

Molecular Insights into Cell-Mediated Immunity in Atypical Non-Ulcerated Cutaneous Leishmaniasis.

Batista L, Sandoval Pacheco C, Flores G, Ferreira F, Goncalves A, Sosa-Ochoa W Microorganisms. 2025; 13(2).

PMID: 40005779 PMC: 11858551. DOI: 10.3390/microorganisms13020413.

Exploring potential therapeutic targets for small cell lung cancer based on transcriptomics combined with Mendelian randomization analysis.

Liao Z, Jia P, Li Y, Zheng Z, Zhang J Front Immunol. 2025; 15:1464259.

PMID: 39872525 PMC: 11769988. DOI: 10.3389/fimmu.2024.1464259.

Mendelian Randomization Validates the Immune Landscape Mediated by Aggrephagy in Esophageal Squamous Cell Carcinoma Patients from the Perspectives of Multi-omics.

Yu H, Si G, Si F J Cancer. 2024; 15(7):1940-1953.

PMID: 38434988 PMC: 10905403. DOI: 10.7150/jca.93376.

References

Zhao L, Cheng S, Fan L, Zhang B, Xu S . TIM-3: An update on immunotherapy. Int Immunopharmacol. 2021; 99:107933. DOI: 10.1016/j.intimp.2021.107933. View

Ma Y, Hein E, Munthe-Fog L, Skjoedt M, Bayarri-Olmos R, Romani L . Soluble Collectin-12 (CL-12) Is a Pattern Recognition Molecule Initiating Complement Activation via the Alternative Pathway. J Immunol. 2015; 195(7):3365-73. DOI: 10.4049/jimmunol.1500493. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Dai X, Ding Z, Tan Y, Bao H, Wang D, Zhang H . Neutrophils inhibit CD8 T cells immune response by arginase-1 signaling in patients with sepsis. World J Emerg Med. 2022; 13(4):266-273. PMC: 9233973. DOI: 10.5847/wjem.j.1920-8642.2022.068. View

Elola M, Capurro M, Barrio M, Coombs P, Taylor M, Drickamer K . Lewis x antigen mediates adhesion of human breast carcinoma cells to activated endothelium. Possible involvement of the endothelial scavenger receptor C-type lectin. Breast Cancer Res Treat. 2006; 101(2):161-74. PMC: 2288708. DOI: 10.1007/s10549-006-9286-9. View

Kobayashi H, Enomoto A, Woods S, Burt A, Takahashi M, Worthley D . Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(5):282-295. DOI: 10.1038/s41575-019-0115-0. View

Acharya N, Sabatos-Peyton C, Anderson A . Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020; 8(1). PMC: 7326247. DOI: 10.1136/jitc-2020-000911. View

Zhang X, Li S, Malik I, Do M, Ji L, Chou C . Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature. 2023; 619(7970):616-623. PMC: 10719927. DOI: 10.1038/s41586-023-06256-5. View

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

10.

Lee Y, Radford K . The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019; 348:123-178. DOI: 10.1016/bs.ircmb.2019.07.006. View

11.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

12.

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

13.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

14.

Pittet M, Michielin O, Migliorini D . Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022; 19(6):402-421. DOI: 10.1038/s41571-022-00620-6. View

15.

Chang L, Hsu W, Kao M, Chou C, Lin C, Liu C . Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases. Sci Rep. 2018; 8(1):3821. PMC: 5830506. DOI: 10.1038/s41598-018-20957-2. View

16.

van Dalen F, van Stevendaal M, Fennemann F, Verdoes M, Ilina O . Molecular Repolarisation of Tumour-Associated Macrophages. Molecules. 2018; 24(1). PMC: 6337345. DOI: 10.3390/molecules24010009. View

17.

Tanaka A, Sakaguchi S . Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019; 49(8):1140-1146. DOI: 10.1002/eji.201847659. View

18.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

19.

Zhao L, Liu Y, Zhang S, Wei L, Cheng H, Wang J . Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022; 13(4):378. PMC: 9021207. DOI: 10.1038/s41419-022-04821-w. View

20.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View